Novartis has announced plans to build an influenza vaccine manufacturing plant in Holly Springs, North Carolina. Construction is expected to begin in 2007.
A total investment of approximately $600 million, which includes a recent $220 million award from the US Department of Health and Human Services, is planned to complete the Holly Springs site.
Once completed and approved for commercial production, the planned Holly Springs site is expected to annually produce up to 50 million doses of seasonal flu vaccines, which will be for use in the US. In the event of an influenza pandemic, the site is planned to have a capacity of up to 150 million monovalent doses annually within six months of a pandemic declaration.
